Greg Democko

Q: What is Greg Democko email address?

Email Greg Democko at gdemocko@chimerix.com. This email is the most updated Greg Democko email found in 2026.

Q: How to contact Greg Democko?

To contact Greg Democko send an email to gdemocko@chimerix.com. (updated on October 30, 2024)

Principal Scientist at Chimerix, Inc. | Raleigh, North Carolina, United States

About Greg Democko

Greg Democko serves as a Principal Scientist at Chimerix, Inc., where he leverages his extensive background in analytical chemistry to drive innovative solutions in pharmaceutical product development. With over a decade of management experience, Greg leads a dynamic Stability Testing Group, where he oversees a team of scientists dedicated to ensuring the integrity and efficacy of drug products through rigorous stability studies. His expertise in analytical method validation and transfer is critical in maintaining compliance with ICH guidelines and FDA regulations, ensuring that all products meet the highest standards of quality and safety.

Currently, Greg is the analytical project lead for a significant oral suspension project being developed and manufactured at a Contract Manufacturing Organization (CMO). In this role, he manages outsourced analytical testing and associated budgets across multiple Contract Research Organizations (CROs), fostering strong relationships to ensure project deliverables and timelines are met. His responsibilities include overseeing analytical testing activities for method development, validation, and batch release of the oral suspension drug product, where he critically reviews and tabulates data to support regulatory submissions.

Greg's proficiency in High-Performance Liquid Chromatography (HPLC) and LC-MS techniques enhances his ability to conduct thorough data analysis, contributing to the successful advancement of drug discovery initiatives. His commitment to maintaining Standard Operating Procedures (SOPs) and his experience with Investigational New Drug (IND) applications further solidify his role as a key contributor to Chimerix's mission of developing transformative therapies for patients in need. With a proven track record of delivering results in a fast-paced pharmaceutical environment, Greg continues to be a driving force in the advancement of innovative drug development processes.

Greg Democko Work